Protection expands coverage for combinations of Provectus Bio’s intralesional PV-10 therapeutic.
Reinforcing the protection of its novel halogenated xanthenes therapeutic platform, late-stage biotech developer Provectus Biopharmaceuticals announced that the U.S. Patent and Trademark Office granted U.S. patent (“USP”) 9,839,688 for the combination of intralesional (“IL”) PV-10 with systemic immunomodulatory therapy, including anti-PD-1 and anti-PD-L1 agents, for the treatment of solid tumor cancers.
Provectus explained that the new patent is a continuation of USP 9,107,887, the company’s first combination therapy patented in 2015. That first patent was followed by a second in November 2017, with the company noting Pfizer as co-assignee on all three patents.
Provectus’ candidates are based on halogenated xanthenes. Intralesional PV-10, the company’s first small-molecule oncolytic immunotherapy results in the necrosis of tumor cells and the release of High Mobility Group Box 1. Chairman of the Company’s Board of Directors, Dominic Rodrigues, explained, “This third patent represents our further efforts to increase the potential commercial value of Provectus’ clinical development program in cancer combination therapy.” Notably, he said, the new addition to the company’s patent estate includes coverage for multiple solid tumor cancers “that are already in our research and development pipeline.”
“Over time,” Rodrigues added, “Provectus and our research and clinical collaborators have jointly or independently shown, on a preclinical or clinical basis, the combination of PV-10 and another class of agent or therapy, including checkpoint inhibition, chemotherapy, and radiation, in multiple cancer indications, including hepatocellular carcinoma, melanoma and pancreatic cancer.” Currently, Intralesional PV-10 is undergoing clinical trials in the study of adult solid tumor cancers, including cancers of the liver and melanoma. It is also in a preclinical study for pediatric cancers.